Minimally invasive implant for benign prostatic hyperplasia

ProVerum has developed a minimally invasive implant for patients with symptomatic Benign Prostatic Hyperplasia (BPH) as an alternative to invasive surgery. ProVerum 2.0 will create a flexible delivery system allowing easier insertion. The project will also assess the route to market for the device.


BPH is an enlargement of the prostate causing difficulty with urination and is one of the most common medical conditions affecting men, with 50% over 60 years impacted. ProVerum offers a safer, less costly alternative, with fewer side effects. The project originated in the (EIT Health Partner) BioInnovate Programme, where the Co-Founder, Dr Conor Harkin, was a Fellow in 2013. An “unmet clinical need” for a less invasive treatment for BPH was identified.


ProVerum Medical (Ireland), including Dr Conor Harkin and Co-Founder Dr Ríona Ní Ghriallais, will co-ordinate the project in conjunction with Urology Professor Thomas Lynch and his colleagues at Trinity College Dublin (Ireland), Fraunhofer Centre for International Management and Knowledge Economy IMW (Germany) and Genesis Biomed (Spain). The consortium brings together international clinical, R&D and business expertise.

The project

The ProVerum device is an implant for the treatment of benign prostatic enlargement. This project will:

  • Optmise the ProVerum delivery system; ensuring it is suitable for insertion under local anaesthetic in a day-case setting.
  • Plan the route to market and update the business plan, with insights into entry to the German and Spanish markets for the ProVerum device.

EIT Health has contributed to the ProVerum project from the beginning. In 2016, the project won a €50 000 Headstart grant from EIT Health, and that support enabled the company to spin out from Trinity College Dublin. The team also took part in the 2016 EIT Health Launchlab programme, which enabled market validation.


The project has positive impacts for:

  • Doctors, who can take advantage of an easier, safer alternative to surgery that has fewer side effects.
  • Patients, who can avoid surgery and reduce risks of re hospitalisation with this effective, less-invasive implant.
  • Healthcare systems, which can avoid the costs associated with surgery and re-hospitalisation.
Why this is an EIT Health Project

This project is in keeping with the EIT Health Focus Area of “Improving Care Pathways”, because a less-invasive treatment for BPH promises to improve outcomes for patients and reduce complications related to surgery.

Dr. Conor Harkin (CSO)
| | ProVerum